Viewing nowPodag 10 mg (Dapagliflozin Propanediol Hydrate)
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
IYON Pharmaceutical Co., Ltd.

MFDS item code 202202288 · Approved 2022.05.30 · Insurance code 658604760
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes more effectively control their blood sugar levels while following diet and exercise regimens. It can be used alone or in combination with other medications and is particularly useful for patients whose blood sugar control is inadequate. Additionally, for patients with cardiovascular disease or risk factors for such disease, this medication may help reduce the occurrence of cardiovascular events, so it should be used safely according to a doctor's instructions. This medication is used to improve blood sugar control in type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other blood glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior history of antidiabetic drug treatment who are receiving this medicine in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR < 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. Tablets should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients with an allergy to its active ingredients or additives. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains lactose; therefore, patients with lactose intolerance, galactose intolerance, lactose deficiency or glucose-galactose malabsorption should not take it. Patients undergoing dialysis should not be administered this medication. It should be used cautiously in patients with decreased fluid volume or impaired kidney function. This medication can lower blood pressure or decrease intravascular volume, potentially causing symptomatic hypotension or acute kidney injury; thus, fluid status and kidney function must be evaluated prior to administration and monitored periodically during treatment. Particularly, elderly patients, those with reduced kidney function, or those on diuretics are at higher risk for hypotension or volume depletion and require careful monitoring. The blood sugar control effect of this medication varies depending on kidney function; therefore, it is advisable not to use it for blood sugar control in patients with severe renal impairment. During the drug treatment, genital infections or urinary tract infections may occur, so immediate treatment should be sought if symptoms of infection arise. Hypoglycemic symptoms may occur, although this is more frequently seen when used in conjunction with insulin or sulfonylureas; thus, dose adjustments may be necessary to mitigate the risk of hypoglycemia when used with these medications. Symptoms of fluid volume depletion or dehydration may arise, so patients with fluid loss, especially due to gastrointestinal disorders, should be closely monitored and may need to temporarily discontinue this medication if necessary. This medication can cause serious metabolic acidosis known as diabetic ketoacidosis; therefore, patients with related symptoms or risk factors should be carefully monitored and treatment should be sought immediately if symptoms are suspected. There is limited experience using this medication in patients with severe hepatic impairment; thus, it should be administered cautiously in patients with liver dysfunction. Elderly patients are at higher risk of reduced kidney function and fluid volume depletion, requiring special caution. Pregnant women should avoid using this medication and should discontinue it immediately if pregnancy is confirmed. Breastfeeding women should also not take this medication, as it may pass into breast milk and affect infants. In cases of overdose, since there is no specific antidote, appropriate treatment according to symptoms should be undertaken and consultation with healthcare providers is recommended if necessary. This medication does not significantly affect the ability to drive or operate machinery, but caution should be exercised regarding hypoglycemia when used in conjunction with insulin or sulfonylureas. Finally, this medication has not been established for safety and efficacy in children, so it is advisable not to use it in this population.
vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, decreased renal creatinine clearance early in treatment, dyslipidemia, elevated serum creatinine early in treatment, elevated serum urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, bile duct stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, dyspepsia, nausea, diarrhea, vomiting, urinary retention, increased serum lactate, lymphocytopenia, vitamin D deficiency, paresthesia, headache, nasopharyngitis, upper respiratory tract infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like syndrome, vaginal discharge, itching, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, at a temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain its effectiveness for a longer period.
Yellow, convex, diamond-shaped film-coated tablets
PTP - 28 tablets/box [28 tablets (7 tablets/PTP x 4)], bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
IYON Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.